Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptomic analysis of an archived bladder cancer cohort

ABSTRACT: Establishment and application of RNAseq based transcriptome analayis on an archivaed bladder cancer cohort.

ORGANISM(S): Homo sapiens

PROVIDER: GSE59483 | GEO | 2017/07/01

SECONDARY ACCESSION(S): PRJNA255416

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Bulk RNAseq data for bladder cancer specimens [UC cohort]

Project description:Bulk RNAseq data for bladder cancer specimens [UC cohort]

| PRJNA929224 | ENA

Bulk RNAseq data for bladder cancer specimens [UC cohort]

Project description:When applying deconvolution methods to bulk RNAseq data, a limitation of most prior studies is the lack of paired scRNA-seq and bulk RNA-seq data from the same samples to serve as ground truth for deconvolution. Our UC cohort, containing matched scRNA-seq and bulk RNA-seq data therefore provided a unique opportunity. (The scRNAseq datasets have been published before [PMID: 32111252 PMID: 36129800 PMID: 36099881 PMID: 33837006 ]. Please see linked manuscript for details) We assembled a scRNA-seq dataset of 100,667 cells from 30 UC tissue samples (20 unique patients). Bulk RNA sequencing was performed on a subset of patients(14) in the single-cell RNA sequencing cohort due to tissue availability.

2024-01-01 | GSE223971 | GEO

Single cell RNA-seq of bladder tissue

Project description:We report the application of single cell RNA-seq for transcript profiling in bladder tissue from Interstitial cystitis/bladder pain syndrome (IC/BPS) with Hunner lesions and without Hunner lesions and normal tissue.

2024-05-23 | GSE175526 | GEO

Context-dependent role of ARF for response to chemotherapy in muscle invasive bladder cancer

Project description:Gene expression profiling analysis (RNAseq) of mouse bladder epithelium from wildtype mice (Arf+/+; p53+/+; Pten+/+) or bladder tumors from Arf-wild-type (Arf+/+; p53f/f; Ptenf/f) or Arfnull (Arff/f; p53f/f; Ptenf/f) mice that had been treated with vehicle or cisplatin

2016-11-15 | GSE89823 | GEO

A microarray meta-dataset of bladder cancer

Project description:We present a meta-dataset comprising of a total of 212 samples including both primary tumors and tumor-free bladder tissues from four independent GEO datasets. To minimise inter-platform variation, only datasets generated from the GPL570 platform (Affymetrix Human Genome U133 Plus 2.0 Array) were processed to develop the meta-dataset. Using multiple open source R packages implemented in our previously developed bioinformatics pipeline, each dataset has been preprocessed with RMA normalisation, merged, and batch effect-corrected via Combat method. With increased sample size, the present meta-dataset serves an excellent 'discovery cohort' for discovering differentially expressed in diseased phenotype.

2019-04-11 | E-MTAB-6696 | biostudies-arrayexpress

RNAseq of bladder cancer samples from Xiangya hospital

Project description:RNAseq of bladder cancer samples from Xiangya hospital

| PRJNA779994 | ENA

Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer

Project description:The progression of conventional urothelial carcinoma (UC) of the bladder to a tumor with a mesenchymal phenotype, referred to as sarcomatoid carcinoma (SARC), is signified by a high propensity for regional and distant metastasis resulting in shorter survival. We report a comprehensive retrospective analysis of 28 cases of SARCs and 84 cases of conventional UCs. A TCGA cohort of 408 muscle-invasive bladder cancers was used as a reference cohort. SARCs showed a distinct mutational landscape with enrichment of p53, PIK3CA, and RB1 mutations. They developed from basal precursor conventional UCs and could be divided into a basal subtype and the most aggressive mesenchymal subtype. Expression analysis showed that SARCs are driven by dysregulation of cell cycle and EMT regulatory networks and nearly half exhibited an immune infiltration phenotype with PDL1 upregulation. Our observations have important implications for prognostication and the development of more effective therapies for this highly lethal variant of bladder cancer.

2019-05-07 | GSE128192 | GEO

Establishment of a Lifetime Cohort of Individuals Surviving Childhood Cancer

Project description:Establishment of a Lifetime Cohort of Individuals Surviving Childhood Cancer

| PRJNA1023683 | ENA

Bladder cancer expression profiling

Project description:Cystoscopic bladder biopsies were obtained from 19 patients and 11 controls between 2004 and 2005. Whole transcript based arrays were used to identify differences in expression profile between cancer and normal, muscle-invasive or non-muscle invasive cancer and normal, grade 1 and grade 3 bladder cancer.

2014-07-01 | E-MTAB-1560 | biostudies-arrayexpress

Identification of nine genomic regions of amplification in bladder cancer, correlation with stage, and potential prognositic and therapeutic value

Project description:We sought to test the hypothesis that ascertainment of genome-wide copy number alterations in bladder cancer may have value for clinical management. We performed a genome wide analysis of 164 bladder cancer samples and 27 bladder cancer cell lines to identify genetic changes associated with disease characteristics. Multiplex inversion probe (MIP) analysis, a newly developed genomic technique, was used to study 80 bladder cancers to identify mutations and copy number changes. Selected amplification events were then analyzed in a validation cohort of 84 bladder cancers by multiplex ligation-dependent probe assay (MLPA). In the MIP analysis, 44 regions of significant copy number change were identified using GISTIC. Nine gene-containing regions of amplification were selected for validation in the second cohort by MLPA. Amplification events at these 9 genomic regions were found to correlate strongly with stage, being seen in only 2 of 23 (9%) Ta grade 1 or 1-2 cancers, in contrast to 31 of 61 (51%) Ta grade 3 and T2 grade 2 cancers, p < 0.001. These observations suggest that analysis of genomic amplification of these 9 regions might serve as a guide for clinical decision making, in terms of management decisions following transurethral resection of bladder cancers. This approach is facilitated by the capability of each of the MIP and MLPA methods to analyze formalin-fixed paraffin-embedded DNA, as done here. Furthermore several of the amplified genes identified here (ERBB2, MDM2, CCND1) render the bladder cancers potentially sensitive to targeted therapy. Copy number profiling was completed for 80 urothelial carcinoma samples using the Affymetrix OncoScan(TM) FFPE Express platform.

2013-04-29 | E-GEOD-44323 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data